The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

Annals of Oncology

Volumn 12, Issue 6, 2001, Pages 745-760

  Pedersen, M W ^a   Meltorn, M ^a   Damstrup, L ^a   Poulsen, H S ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cancer; EGFRvIII; Function; Therapy

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CANERTINIB; CETUXIMAB; CISPLATIN; CP 35877; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GYRASE INHIBITOR; IMMUNOGLOBULIN G2A; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PACLITAXEL; PD 169414; PELITINIB; PKI 116; PROTEIN BCL X; RIBOZYME; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIARRHEA; DIMERIZATION; DRUG DESIGN; DRUG STRUCTURE; FEVER; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; VACCINATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BCL-X PROTEIN; GENE DELETION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0034954124     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011177318162     Document Type: Review

References (106)

1. The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription
2. EGF receptor amplification and expression in human brain tumours
3. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells
4. Epidermal growth factor receptor (EGFr) expression in non-small-cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype
5. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts
6. Epidermal growth factor receptor (EGFR) biology and human oral cancer
7. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
8. The autocrine loop of TGF-alpha/EGFR and brain tumors
9. Expression of mutated epidermal growth factor receptor by non-small-cell lung carcinomas
10. EGFR gene amplification-rearrangement in human glioblastomas
11. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor
12. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
13. Genetic aberrations in human brain tumors
14. A complete description of the EGF-receptor exon structure: Implication in oncogenic activation and domain evolution
15. Regulation of epidermal growth factor receptor expression and activation: A brief review
16. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
17. Structural alterations of the epidermal growth factor receptor gene in human gliomas
18. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
19. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor
20. Epidermal growth factor
21. The epidermal growth factor
22. Disulfide bond structure of human epidermal growth factor receptor
23. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target
24. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor
25. Structural analysis of the transmembrane domain of the epidermal growth factor receptor
26. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
27. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
28. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
29. The intracellular tyrosine kinase domain of the epidermal growth factor receptor undergoes a conformational change upon autophosphorylation
30. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway
31. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor
32. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
33. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase
34. CD16-mediated activation of phosphatidylinositol-3 kinase (PI-3K) in human NK cells involves tyrosine phosphorylation of Cbl and its association with Grb2, Shc, pp36 and p85 PI-3K subunit
35. New role for shc in activation of the phosphatidylinositol 3-Kinase/Akt pathway [In Process Citation]
36. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor
37. Specificity of receptor tyrosine kinase signaling: Transient vs. sustained extracellular signal-regulated kinase activation
38. Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts
39. The Bcl-2 protein family: Arbiters of cell survival
40. Bcl-2 family: Life-or-death switch
41. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
42. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
43. Evidence for a PI 3-kinase and JNK dependent but AKT independent cell survival pathway
44. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
45. Function of aberrant EGFR in malignant gliomas
46. Epidermal growth factor ligand-independent, unregulated, cell- transforming potential of a naturally occurring human mutant EGFRvIII gene
47. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
48. Epidermal growth factor receptor mutation type III transfected into a small-cell lung cancer cell line is predominantly localized at the cell surface and enhance tumourigenicity
49. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
50. Role of an anti-epidermal growth factor receptor in treating cancer
51. Epidermal growth factor-related peptides and their receptors in human malignancies
52. Small molecule inhibitors of receptor tyrosine kinases
53. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilino-quinazolines
54. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice [In Process Citation]
55. Combinatorial chemoprevention of intestinal neoplasia
56. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
57. ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Correlation of c-fos expression and expression and tumour growth inhibition
58. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
59. A Pharmacokinetic/pharmacodynamic trial of ZD1839 ('IRESSA'), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with five selected tumor types (a phase I-II trial of continuous once-daily treatm
60. Phase I study of oral ZD1839 ('Iressa'), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
61. ZD1839 ('IRESSA'), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): Pharmacokinetic results of a phase I study in patients with advanced cancer
62. A phase I intermittent dose-escalation trial of ZD1839 ('IRESSA') in Japanese patients with solid malignant tumors
63. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
64. 18FDG-PET evaluation of patients treated with the epidermal growth factor (EGFR) tyrosine kinase (TK) inhibitor
65. A phase II trial of the EGFR tyrosine kinase inhibitor (TKI), CP-358,774, following platinium-based chemotherapy in patients (pts) with advanced non-small-cell lung cancer
66. A phase II, multi-center study of the EGFR tyrosine kinase inhibitor (TKI), CP-358,774, in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
67. EKB-569: A new irreversible inhibitor of EGFR tyrosine kinase for the treatment of cancer
68. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
69. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
70. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
71. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
72. Therapeutic potential of chimeric and murine anti- (epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
73. Antitumor activity of sequential treatment with topotecan and anti- epidermal growth factor receptor monoclonal antibody C225
74. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
75. Safety profile of the monoclonal antibody (MoAb) IMC-C255, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors
76. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody C225 alone in patients (pts) with metastic renal carcinoma (RCC)
77. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
78. A phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC)
79. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (pts) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
80. Phase I trial of chimerized anti-epidermal growth factor receptor (Anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
81. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment
82. In vitro and in vivo stability and anti-tumour efficacy of an anti- EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody
83. Clinical experience with CD64-directed immunotherapy. An overview
84. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors
85. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein
86. Monoclonal antibody therapy of human gliomas: Current status and future approaches
87. Gene inhibition using antisense oligodeoxynucleotides
88. EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells
89. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
90. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor
91. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
92. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
93. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1 [In Process Citation]
94. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors
95. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA [In Process Citation]
96. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression
97. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
98. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo
99. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
100. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
101. An EGFRvIII-specific peptide vaccine generates antitumor immunity through a humoral pathway
102. Pharmacodynamic effects of Iressa, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in skin biopsies from cancer patients participating in a phase I trial
103. A phase I, dose escalation, pharmacokinetics (PK) and pharmacodynamic (PD) study of ZD1839: NCIC CTG IND.122
104. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
105. New technologies in epidermal growth factor receptor-targeted cancer therapy
106. Glycosylation-induced conformational modification positively regulates receptor-receptor association